Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Lung Neoplasms 23Carcinoma, Hepatocellular 23Small Cell Lung Carcinoma 16Cholangiocarcinoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Biliary Tract Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Liver Neoplasms 8Pancreatic Neoplasms 6Carcinoma 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2

Interventions

pembrolizumab 2erdafitinib 2Gemcitabine 2Cisplatin 2Carboplatin 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Tiragolumab 1Midazolam 1Metformin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Cancer × durvalumab × 90 days × Clear all
NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡